Febuxostat in patients with hyperuricemia and gout: is the nephroprotective effect real?
Hyperuricemia (HU) and gout are independent risk factors for chronic kidney disease (CKD). Worldwide, the increasing prevalence of CKD leads to a deterioration in the quality and duration of life of patients and an increase in mortality. If HU plays a significant role in the development of renal fai...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2024-10-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1651 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242048792625152 |
|---|---|
| author | M. S. Eliseev Ya. I. Kuzmina |
| author_facet | M. S. Eliseev Ya. I. Kuzmina |
| author_sort | M. S. Eliseev |
| collection | DOAJ |
| description | Hyperuricemia (HU) and gout are independent risk factors for chronic kidney disease (CKD). Worldwide, the increasing prevalence of CKD leads to a deterioration in the quality and duration of life of patients and an increase in mortality. If HU plays a significant role in the development of renal failure, then lowering high uric acid (UA) levels should theoretically contribute to the improvement of kidney function. The main method of lowering UA levels is administration of a urate-lowering therapy – xanthine oxidase (XO) inhibitors. The nephroprotective effect of one of the XO inhibitors, febuxostat has been demonstrated in animal models.The article analyzes the currently available data on the use of febuxostat in patients with HU and gout and different levels of renal function impairment and discusses the possible mechanisms of the drug's nephroprotective effect. |
| format | Article |
| id | doaj-art-5d9b742f4cc74bc5b98123784b0133dc |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2024-10-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-5d9b742f4cc74bc5b98123784b0133dc2025-08-20T03:59:56ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2024-10-0118513514010.14412/1996-7012-2024-5-135-1402730Febuxostat in patients with hyperuricemia and gout: is the nephroprotective effect real?M. S. Eliseev0Ya. I. Kuzmina1V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyHyperuricemia (HU) and gout are independent risk factors for chronic kidney disease (CKD). Worldwide, the increasing prevalence of CKD leads to a deterioration in the quality and duration of life of patients and an increase in mortality. If HU plays a significant role in the development of renal failure, then lowering high uric acid (UA) levels should theoretically contribute to the improvement of kidney function. The main method of lowering UA levels is administration of a urate-lowering therapy – xanthine oxidase (XO) inhibitors. The nephroprotective effect of one of the XO inhibitors, febuxostat has been demonstrated in animal models.The article analyzes the currently available data on the use of febuxostat in patients with HU and gout and different levels of renal function impairment and discusses the possible mechanisms of the drug's nephroprotective effect.https://mrj.ima-press.net/mrj/article/view/1651hyperuricemiagouturate-lowering therapyfebuxostatchronic kidney diseaserenal failure |
| spellingShingle | M. S. Eliseev Ya. I. Kuzmina Febuxostat in patients with hyperuricemia and gout: is the nephroprotective effect real? Современная ревматология hyperuricemia gout urate-lowering therapy febuxostat chronic kidney disease renal failure |
| title | Febuxostat in patients with hyperuricemia and gout: is the nephroprotective effect real? |
| title_full | Febuxostat in patients with hyperuricemia and gout: is the nephroprotective effect real? |
| title_fullStr | Febuxostat in patients with hyperuricemia and gout: is the nephroprotective effect real? |
| title_full_unstemmed | Febuxostat in patients with hyperuricemia and gout: is the nephroprotective effect real? |
| title_short | Febuxostat in patients with hyperuricemia and gout: is the nephroprotective effect real? |
| title_sort | febuxostat in patients with hyperuricemia and gout is the nephroprotective effect real |
| topic | hyperuricemia gout urate-lowering therapy febuxostat chronic kidney disease renal failure |
| url | https://mrj.ima-press.net/mrj/article/view/1651 |
| work_keys_str_mv | AT mseliseev febuxostatinpatientswithhyperuricemiaandgoutisthenephroprotectiveeffectreal AT yaikuzmina febuxostatinpatientswithhyperuricemiaandgoutisthenephroprotectiveeffectreal |